A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy and safety of successful interventional therapy and unblocked blood vessel maintaining in the treatment of coronary in-stent restenosis by paclitaxel -eluting PTCA- balloon catheter (3μg/mm2 balloon surface area) versus paclitaxel-eluting stent Taxus® Liberte, and the reference diameter of coronary artery stenosis is 2.5mm-4.0mm and the length ≤30mm.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions

NCT00670436

Coronary Artery Disease Chronic Total Occlusion Native Coronary Artery

COMPLETED PHASE2

Evaluation of the Efficacy and Safety of a Paclitaxel Eluting PTCA Balloon Catheter in Coronary In-stent Restenosis

NCT04213378

Coronary In-stent Restenosis

UNKNOWN PHASE2/PHASE3

Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis

NCT01967199

Coronary Restenosis

TERMINATED PHASE4

Paclitaxel Eluting Balloon Versus Drug Eluting Stent in Native Coronary Artery Stenoses of Diabetic Patients

NCT00462631

Coronary Stenosis Diabetes Mellitus

COMPLETED PHASE2/PHASE3

Efficacy Study of Paclitaxel-eluting Balloon, -Stent vs. Plain Angioplasty for Drug-eluting Stent Restenosis

NCT00987324

Heart Disease Ischemia Restenosis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Instent Restenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SeQuent® Please

Paclitaxel Drug-eluting Coronary Artery Balloon Catheter

Group Type EXPERIMENTAL

SeQuent® Please

Intervention Type DEVICE

SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial

Taxus Liberte

Paclitaxel Drug-eluting Coronary Stent and Conveying System

Group Type ACTIVE_COMPARATOR

Taxus Liberte

Intervention Type DEVICE

Taxus Liberte with a length of 8mm,12mm,16mm,20mm and 24mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SeQuent® Please

SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial

Intervention Type DEVICE

Taxus Liberte

Taxus Liberte with a length of 8mm,12mm,16mm,20mm and 24mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Paclitaxel Drug-eluting Coronary Artery Balloon Catheter Paclitaxel Drug-eluting Coronary Stent and Conveying System

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Related to patients

* Patients with stable angina, unstable angina, old myocardial infarction or proven asymptomatic ischemia
* Restenosis after the first stent implant
* Patients who can receive any kind of coronary revascularization (including balloon angioplasty, stent implantation or coronary artery bypass grafting)
* Patient aged 18-80 (including 18 and 80)
* Female patients of childbearing age in the study period shall not be pregnant or protocol to be pregnant, it is suggested that patients shall take sufficient contraception measures till (including) the follow-up visit of month 9
* Patients who agree to accept the angiography follow-up visits of month 9
* Patients who agree to accept the clinical visits at Day 30, Month 6 and Month 12
* Patients can understand the study objectives psychologically and linguistically and show the sufficient compliance to the study protocol. Patients present acceptance of the risks and benefits described in the informed consent form.
2. Related to lesion

* Drug-eluting stent restenosis: Type Mehran I, Type II and Type III; the reference blood vessel diameter is 2.5 mm-4.0 mm, length ≤30mm
* Before surgery, stenosis diameter must be ≥70% or ≥50% and accompanied by ischemia
* The distance between other lesion requires interventional therapy and the target lesion must be \>10mm
* In the stent group, up to two paclitaxel drug stents are permitted to be implanted in series

Exclusion Criteria

1. Related to patients

* Patients with myocardial infarction within one week
* Patients with severe congestive heart failure or NYHA IV severe heart failure
* Patients with severe valvular heart disease
* Female patients in pregnancy or lactation
* Patients with the life expectancy not exceeding 1 year or the factors causing difficult clinical follow-up visits
* Patients with hemorrhagic tendency, prohibited to take anticoagulants or antiplatelet drugs
* Patients with stroke within 6 months before the surgery
* Patients taking part in any other clinical tests
* Existing sever renal failure (GFR\<30ml/min) or the history, so not meeting the conditions of angiography
* Patients with cardiac transplantation
* Patients not included for other reasons from the investigators
2. Related to lesion

* Evidence of extensive thrombus in target blood vessel before the intervention
* Percutaneous coronary intervention for many in-stent restenosis lesions in same artery
* 3-vessel disease that all need to be intervented
* In bifurcation lesions, branch open blood vessel diameter ≥2.5mm
* Percutaneous coronary intervention of venous graft
* Entire shut of Grade TIMI 0 blood flow (Type Mehran IV stenosis)
* Open lesion at left primary and within 2mm
3. Related to concomitant therapy

* Patients cannot tolerate aspirin and/or clopidogrel, patients with the history of neutrocytopenia or thrombocytopenia, or patients with severe hypohepatia and prohibited to take clopidogrel
* Patients known allergic to paclitaxel
* Patients with the history of leucopenia (numeration of leukocytes \<3x109/L, exceeding 3 days), neutrocytopenia (ANC\<1000 neutrocytes/mm3, exceeding 3 days) or thrombocytopenia (\<100,000 platelets/mm3
* Patients with the history of peptic ulcer or gastrointestinal hemorrhage in the past 6 months

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No